Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott Ely, MD MPH

Blood (2015) 126 (23): 2991.

https://doi.org/10.1182/blood.V126.23.2991.2991

Published: 2015

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Tomer Mark, MD, Morton Coleman, MD, David S Jayabalan, BSMS, Roger Pearse, MD/PhD, Faiza Zafar, PA, Scott Ely, MD, MPH, Megan C. Manco, Mary Crann, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2009) 114 (22): 1861.

https://doi.org/10.1182/blood.V114.22.1861.1861

Published: 2009

Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1877.

https://doi.org/10.1182/blood.V114.22.1877.1877

Published: 2009

Journal Articles

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

Jia Ruan, MD, PhD, Peter Martin, Richard R Furman, MD, Julie M. Vose, MD, Ann LaCasce, MD, Ying-Kuen K. Cheung, PhD, Jennifer O'Loughlin, Rebecca Elstrom, MD, Ruben Niesvizky, MD, Amy Chadburn, MD, Scott Ely, MD, Ethel Cesarman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2009) 114 (22): 2682.

https://doi.org/10.1182/blood.V114.22.2682.2682

Published: 2009

Journal Articles

MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.

Hearn J. Cho, MD, PhD, Anna Mei, Tricia Nardiello, Maurizio DiLiberto, Xiangao Huang, Jennifer E Amengual, MD, Achim Jungbluth, MD, Scott Ely, MD, MPH, Ruben Niesvizky, MD, David S Jayabalan, BSMS, Lloyd Old, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1795.

https://doi.org/10.1182/blood.V114.22.1795.1795

Published: 2009

Journal Articles

ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.

Peter Martin, Amy Chadburn, MD, Wayne Tam, Lauren Tyrell, Rebecca Elstrom, MD, Jia Ruan, MD, PhD, Morton Coleman, Scott Ely, MD, MPH, Daniel M. Knowles, John P. Leonard, Richard R Furman

Blood (2009) 114 (22): 4686.

https://doi.org/10.1182/blood.V114.22.4686.4686

Published: 2009

Journal Articles

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Rentian Feng, PhD, Xiangao Huang, PhD, Les Coulton, PhD, Hendrik De Raeve, MD, Maurizio DiLiberto, PhD, Scott Ely, MD, MPH, Guozhi Xiao, PhD, Min Luo, MD, Eline Menu, PhD, Peter Croucher, MD, G. David Roodman, MD, PhD, Karin Vanderkerken, MD, Selina Chen-Kiang, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 298.

https://doi.org/10.1182/blood.V114.22.298.298

Published: 2009

Journal Articles

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD, MPH, David S Jayabalan, BSMS, Isan Chen, MD, Keith D. Wilner, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 299.

https://doi.org/10.1182/blood.V114.22.299.299

Published: 2009

Journal Articles

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Tracey Louie, B.Sc., David S Jayabalan, B.Sc., Scott Ely, MD, MPH, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2008) 112 (11): 3678.

https://doi.org/10.1182/blood.V112.11.3678.3678

Published: 2008

Journal Articles

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Y. Lynn Wang, PhD, Richard Lent, MD, Paul J. Christos, MPH, Joong W. Lee, PhD, Yashpal P. Agrawal, MD/PhD, Susan Matthews, PhD, Scott Ely, MD, Madhu Mazumdar, PhD, Ethel Cesarman, MD, April Rambo, RN, John P. Leonard, MD, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 2737.

https://doi.org/10.1182/blood.V110.11.2737.2737

Published: 2007

Journal Articles

Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.

Jessica L. Stern, Brian Di Carlo, MD, Michael W. Schuster, MD, Tsiporah B. Shore, MD, John G. Harpel, MD,PhD, Roger Pearse, MD,PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 2953.

https://doi.org/10.1182/blood.V108.11.2953.2953

Published: 2006

Journal Articles

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6.

Linda B. Baughn, PhD, Maurizio Di Liberto, PhD, Kaida Wu, PhD, Peter Toogood, PhD, Tracey Louie, Rachel Gottschalk, Ruben Niesvizky, MD, Hearn J. Cho, MD, PhD, Scott Ely, MD, MPH, Malcolm A.S. Moore, D Phil, Selina Chen-Kiang, PhD

Blood (2006) 108 (11): 369.

https://doi.org/10.1182/blood.V108.11.369.369

Published: 2006

Journal Articles

Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.

Hearn J. Cho, MD, PhD, Scott Ely, MD, Wayne R. Austin, AB, Ruben Niesvizky, MD, Roger Pearse, MD, PhD, Morton Coleman, MD, Nina Bhardwaj, MD, PhD, Maurizio DiLiberto, PhD, Selina Chen-Kiang, PhD, Lloyd J. Old, MD, Achim A. Jungbluth, MD

Blood (2006) 108 (11): 3397.

https://doi.org/10.1182/blood.V108.11.3397.3397

Published: 2006

Journal Articles

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Brian A. Di Carlo, MD, Jessica L. Stern, Michael Schuster, MD, Tsiporah Shore, MD, John Harpel, MD, PhD, Roger Pearse, MD, PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, MA, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 3538.

https://doi.org/10.1182/blood.V108.11.3538.3538

Published: 2006

Journal Articles

Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.

Selina Chen-Kiang, PhD, Scott Ely, MD, MPH, Maurizio Di Liberto, PhD, Kaida Wu, PhD, John Shaughnessy, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Eunice Hatada, PhD

Blood (2005) 106 (11): 1564.

https://doi.org/10.1182/blood.V106.11.1564.1564

Published: 2005

Journal Articles

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Scott Ely, MD, MPH, Maurizio DiLiberto, PhD, Hearn J. Cho, MD, PhD, Udi Y. Gelbshtein, David S. Jayabalan, Sangeeta Aggarwal, MD, Janice L. Gabrilove, MD, Roger N. Pearse, MD, PhD, Karen Pekle, RN, ANPC, Faiza Zafar, RPAC, Zoe Goldberg, MD, John P. Leonard, MD, John J. Wright, MD, Selina Chen-Kiang, PhD, Morton Coleman, MD

Blood (2005) 106 (11): 2574.

https://doi.org/10.1182/blood.V106.11.2574.2574

Published: 2005

NARROW

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.

ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6.

Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only